Skip to content

Follow your curiosity.

Try “brain”, “genomics”, or another subject you follow.

General Biotech · The big question

Teaching AI to smell: A new model mimics the brain's olfactory system

Low rank adaptation of chemical foundation models generate effective odorant representations

Editorial illustration for Low rank adaptation of chemical foundation models generate effective odorant representations
Editorial illustration

Summary

Predicting how a certain chemical will smell is a notoriously tricky puzzle. Two molecules can look almost identical in their chemical structure but trigger completely different reactions in our noses and brains. Scientists have tried using massive artificial intelligence systems, known as foundation models, to predict these odor matches. However, out of the box, these general AI tools do not perform much better than older, hand-calculated methods. Both approaches end up looking at the same basic physical and chemical traits, leaving a lot of room for improvement.

To bridge this gap, researchers developed a new system called LORAX. Instead of relying on a general understanding of chemistry, LORAX fine-tunes these existing AI models to focus specifically on the biology of smell. Using specialized training techniques, the model adjusts its focus to better understand how molecules actually bind to scent receptors in the body.

This tailored approach worked. The researchers found that LORAX significantly outperforms previous models. It succeeds by organizing chemical information in a way that closely mirrors how our actual olfactory neurons, or smell-sensing brain cells, process odors. However, it is important to note that this research is currently based on early computer simulations of receptor binding, and the specific accuracy numbers or sample sizes are not yet detailed.

Why it matters.

Cracking the code of how chemical structures translate into perceived smells has long been a major goal for scientists. A highly accurate AI model for smell could eventually transform the fragrance, food, and beverage industries by allowing chemists to design new flavors and perfumes entirely on a computer, rather than through costly trial and error.

Furthermore, because this system successfully mimics real neural responses, it offers biologists a powerful new digital tool for understanding the fundamental science of our senses. While still in the computational modeling phase, this targeted approach to AI paves the way for a deeper understanding of how the brain interprets the invisible chemical world around us.

From the source

The story in numbers.

Novel fine-tuned model introduced (LORAX)
1
Quantitative performance metrics (not provided in abstract)
N/A
Keep the context

Follow the evidence.

This source is a preprint and has not completed peer review. Its findings are provisional.

Your next discovery.

Keep exploring ↗
General Biotech

Maryland sets a $274 monthly price cap on the diabetes drug Ozempic

The state of Maryland is taking a major step to rein in the cost of prescription medications. The Maryland Prescription Drug Affordability Board recently decided to set a strict price limit on Ozempic, a widely used treatment for type 2 diabetes. By establishing what is known as an upper payment limit, the board aims to make the medication more affordable for state budgets. Under this new rule, the cost of Ozempic will be capped at $274 for a standard 30-day supply. To come up with this number, the board looked at the maximum fair price that Medicare currently pays for the drug and used it as a benchmark. State officials estimate that this single price cap will save Maryland about $5.8 million every year. However, everyday consumers will not see these savings immediately. The initial price cap is slated to take effect in January 2027, and it will strictly apply to state and local government health plans. This means the immediate financial relief is limited to public programs rather than individual pharmacy visits for the general public.

STAT News1 min read
General Biotech

FDA shakeups, safety warnings, and a promising obesity pill

The Food and Drug Administration is navigating major leadership transitions, with acting directors Tracy Beth Høeg and Katherine Szarama recently exiting their roles in top drug review offices. Amidst these changes, the agency is facing severe safety concerns regarding Tavneos, a rare disease medication from the pharmaceutical company Amgen. In Japan, twenty patients taking the drug have died, with most of these deaths linked to a severe liver condition called vanishing bile duct syndrome. Following these tragedies and allegations of manipulated clinical trial data, the FDA has asked Amgen to withdraw the drug in the United States, though it currently remains available on the market. In other medical developments, an experimental daily pill for obesity is showing significant promise. Vincentage Pharma reported that patients taking its drug VCT220 in a late-stage Chinese clinical trial lost about twelve percent of their body weight over a year, compared to just one percent for those taking a placebo. However, the drug is still experimental globally, and a broader Phase 2 study is underway with results not expected until late 2026. Meanwhile, the major drugmaker Regeneron has teamed up with an early-stage startup called Parabilis Medicines. They plan to develop new therapies known as "antibody-helicon conjugates," which are designed to reach and treat disease-causing proteins inside cells that conventional methods have traditionally found impossible to target.

BioPharma Dive2 min read
General Biotech

Physical decline starts at 35, but late-in-life exercise boosts fitness

A massive study tracking people in Sweden for almost 50 years has pinpointed exactly when our bodies start to lose their physical edge. Researchers discovered that overall fitness, physical strength, and muscle endurance quietly begin to slip around age 35. Rather than maintaining a slow and steady pace, the researchers noted that the rate of this physical decline actually speeds up as the years go by. However, the study offers a highly encouraging twist for older adults. Even if someone has been inactive for decades, deciding to adopt a physically active lifestyle later in life can still yield major benefits. The researchers found that these late starters actually improved their physical performance by up to 10 percent, proving that the human body remains responsive to exercise well into old age. While tracking individuals over a five-decade span is a remarkable scientific achievement, there are a few limitations to keep in mind. The research is based entirely on a Swedish cohort, so it is unclear if these exact timelines apply to more diverse global populations. Additionally, the initial data does not specify the exact number of participants or the specific medical tests used to measure their fitness levels.

Science Daily1 min read

A little science goes a long way.

Clear, thoughtful biotech briefings. In your inbox three times a week.

Stay curious. Subscribe free ↗